Nuclear Medicine
CLINICAL DECISION SUPPORT
| Clinical Evaluation |
|---|
| Glucose metabolism |
| Type of Imaging |
| PET |
| Grade of Recommendation |
| A (strongly recommended) |
| Level of Evidence |
| well-established clinical and NM recommendations recommendations |
| Effective Dose |
| 19.0 µSv/MBq |
| Bibliographic Reference |
|
Delgado Bolton, R. C., Aide, N., Colletti, P. M., Ferrero, A., Paez, D., Skanjeti, A., ... Giammarile, F. EANM guideline on the role of 2-[18F]FDG... read more Delgado Bolton, R. C., Aide, N., Colletti, P. M., Ferrero, A., Paez, D., Skanjeti, A., ... Giammarile, F. EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging. 2021; https://doi.org/10.1007/s00259-021-05450-9. Salaün, P. Y., Abgral, R., Malard, O., Querellou-Lefranc, S., Quere, G., Wartski, M., ... Cachin, F. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020; https://doi.org/10.1007/s00259-019-04553-8. NCCN guidelines Version: 3.2021. Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., ... Vergote, I. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz062. read less |
| Guide to Nuclear Medicine |
| Read the corresponding chapter |